16 Jul 2009 15:39
Proteome Sciences plc
("Proteome" or the "Company")
Holding(s) in Company
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | Proteome Sciences plc | ||
2 Reason for the notification (please tick the appropriate box or boxes): | |||
An acquisition or disposal of voting rights | Yes | ||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | No | ||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | No | ||
An event changing the breakdown of voting rights | No | ||
Other (please specify): | No | ||
3. Full name of person(s) subject to the notification obligation: iii | Cubana Investments Limited | ||
4. Full name of shareholder(s) (if different from 3.):iv | |||
5. Date of the transaction and date on which the threshold is crossed or reached: v | 19th June 2009 | ||
6. Date on which issuer notified: | 15th July 2009 | ||
7. Threshold(s) that is/are crossed or reached: vi, vii | >11% |
8. Notified details: | |||||||||||||||||
A: Voting rights attached to shares viii, ix | |||||||||||||||||
Class/type of shares if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | |||||||||||||||
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | |||||||||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | |||||||||||||
GB0003104196 | 13,287,183 | 13,287,183 | 15,187,465 | 15,187,465 | 11.44% | ||||||||||||
B: Qualifying Financial Instruments | |||||||||||||||||
Resulting situation after the triggering transaction | |||||||||||||||||
Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights | |||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | |||||||||||||||||
Resulting situation after the triggering transaction | |||||||||||||||||
Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to | % of voting rights xix, xx | ||||||||||||
Nominal | Delta | ||||||||||||||||
Total (A+B+C) | |||||||||||||||||
Number of voting rights | Percentage of voting rights | ||||||||||||||||
15,187,465 | 11.44% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | |
Proxy Voting: | |
10. Name of the proxy holder: | |
11. Number of voting rights proxy holder will cease to hold: | |
12. Date on which proxy holder will cease to hold voting rights: | |
13. Additional information: | |
14. Contact Name: | Mirza Rahman |
15. Contact telephone: | +65 6538 1998 |
Enquiries:
Proteome Sciences plc (01932 865 065) Christopher Pearce, CEO
James Malthouse, FD
Noble & Company Limited (020 7763 2200)John Llewellyn-Lloyd
Sam Reynolds